Superior Planning, LLC’s Corcept Therapeutics CORT Stock Holding History

Superior Planning, LLC’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$2.19K	Buy	+19	New	+$2.04K	﹤0.01%	1530

Other funds holding CORT

Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return

Parallel Advisors San Francisco, California $7.42B AUM 27.68% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 38.25% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Jane Street New York $1.19T AUM 51.51% 1-Year Est. Return

Emerald Advisers Leola, Pennsylvania $3.64B AUM 71.19% 1-Year Est. Return

Superior Planning, LLC's CORT Position: Q3 2026 in Review

Superior Planning, LLC opened a new position in Corcept Therapeutics (CORT) in Q3 2026: 19 shares worth $2.19K. The stake represents ﹤0.01% of the portfolio and ranks #1530 among its holdings.

331 funds tracked by Wall St. Rank hold CORT as of Q3 2026.

Superior Planning, LLC held 19 shares of Corcept Therapeutics worth $2.19K as of Q3 2026.
Corcept Therapeutics was a new Superior Planning, LLC position in Q3 2026.
Corcept Therapeutics made up ﹤0.01% of Superior Planning, LLC's portfolio in Q3 2026, its #1530 holding.
331 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q3 2026.

Based on Superior Planning, LLC's 13F filing for Q3 2026, filed 12 Nov 2026.